Category: predicts

  • New AI predicts inner workings of cells

    New AI predicts inner workings of cells

    In the same way that ChatGPT understands human language, a new AI model developed by Columbia computational biologists captures the language of cells to accurately predict their activities.

    Using a new artificial intelligence method, researchers at Columbia University Vagelos College of Physicians and Surgeons can accurately predict the activity of genes within any human cell, essentially revealing the cell’s inner mechanisms. The system, described in the current issue of Nature, could transform the way scientists work to understand everything from cancer to genetic diseases.

    “Predictive generalizable computational models allow to uncover biological processes in a fast and accurate way. These methods can effectively conduct large-scale computational experiments, boosting and guiding traditional experimental approaches,” says Raul Rabadan, professor of systems biology and senior author of the new paper.

    Traditional research methods in biology are good at revealing how cells perform their jobs or react to disturbances. But they cannot make predictions about how cells work or how cells will react to change, like a cancer-causing mutation.

    “Having the ability to accurately predict a cell’s activities would transform our understanding of fundamental biological processes,” Rabadan says. “It would turn biology from a science that describes seemingly random processes into one that can predict the underlying systems that govern cell behavior.”

    In recent years, the accumulation of massive amounts of data from cells and more powerful AI models are starting to transform biology into a more predictive science. The 2024 Nobel Prize in Chemistry was awarded to researchers for their groundbreaking work in using AI to predict protein structures. But the use of AI methods to predict the activities of genes and proteins inside cells has proven more difficult.

    New AI method predicts gene expression in any cell

    In the new study, Rabadan and his colleagues tried to use AI to predict which genes are active within specific cells. Such information about gene expression can tell researchers the identity of the cell and how the cell performs its functions.

    “Previous models have been trained on data in particular cell types, usually cancer cell lines or something else that has little resemblance to normal cells,” Rabadan says. Xi Fu, a graduate student in Rabadan’s lab, decided to take a different approach, training a machine learning model on gene expression data from millions of cells obtained from normal human tissues. The inputs consisted of genome sequences and data showing which parts of the genome are accessible and expressed.

    The overall approach resembles the way ChatGPT and other popular “foundation” models work. These systems use a set of training data to identify underlying rules, the grammar of language, and then apply those inferred rules to new situations. “Here it’s exactly the same thing: we learn the grammar in many different cellular states, and then we go into a particular condition — it can be a diseased or it can be a normal cell type — and we can try to see how well we predict patterns from this information,” says Rabadan.

    Fu and Rabadan soon enlisted a team of collaborators, including co-first authors Alejandro Buendia, now a Stanford PhD student formerly in the Rabadan lab, and Shentong Mo of Carnegie Mellon, to train and test the new model.

    After training on data from more than 1.3 million human cells, the system became accurate enough to predict gene expression in cell types it had never seen, yielding results that agreed closely with experimental data.

    New AI methods reveal drivers of a pediatric cancer

    Next, the investigators showed the power of their AI system when they asked it to uncover still hidden biology of diseased cells, in this case, an inherited form of pediatric leukemia.

    “These kids inherit a gene that is mutated, and it was unclear exactly what it is these mutations are doing,” says Rabadan, who also co-directs the cancer genomics and epigenomics research program at Columbia’s Herbert Irving Comprehensive Cancer Center.

    With AI, the researchers predicted that the mutations disrupt the interaction between two different transcription factors that determine the fate of leukemic cells. Laboratory experiments confirmed AI’s prediction. Understanding the effect of these mutations uncovers specific mechanisms that drive this disease.

    AI could reveal “dark matter” in genome

    The new computational methods should also allow researchers to start exploring the role of genome’s “dark matter” — a term borrowed from cosmology that refers to the vast majority of the genome, which does not encode known genes — in cancer and other diseases.

    “The vast majority of mutations found in cancer patients are in so-called dark regions of the genome. These mutations do not affect the function of a protein and have remained mostly unexplored. says Rabadan. “The idea is that using these models, we can look at mutations and illuminate that part of the genome.”

    Already, Rabadan is working with researchers at Columbia and other universities, exploring different cancers, from brain to blood cancers, learning the grammar of regulation in normal cells, and how cells change in the process of cancer development.

    The work also opens new avenues for understanding many diseases beyond cancer and potentially identifying targets for new treatments. By presenting novel mutations to the computer model, researchers can now gain deep insights and predictions about exactly how those mutations affect a cell.

    Coming on the heels of other recent advances in artificial intelligence for biology, Rabadan sees the work as part of a major trend: “It’s really a new era in biology that is extremely exciting; transforming biology into a predictive science.”

  • New AI tool predicts protein-protein interaction mutations in hundreds of diseases

    New AI tool predicts protein-protein interaction mutations in hundreds of diseases

    Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication.

    The computational tool is called PIONEER (Protein-protein InteractiOn iNtErfacE pRediction). Researchers demonstrated PIONEER’s utility by identifying potential drug targets for dozens of cancers and other complex diseases in a recently published Nature Biotechnology article.

    Genomic research is key in drug discovery, but it is not always enough on its own, says Feixiong Cheng, PhD, study co-lead author and director of Cleveland Clinic’s Genome Center. When it comes to making medications based on genomic data, the average time between discovering a disease-causing gene and entering clinical trials is 10-15 years.

    “In theory, making new medicines based on genetic data is straightforward: mutated genes make mutated proteins,” Dr. Cheng says. “We try to create molecules that stop these proteins from disrupting critical biological processes by blocking them from interacting with healthy proteins, but in reality, that is much easier said than done.”

    One protein in our body can interact with hundreds of other proteins in many different ways. Those proteins can then interact with hundreds more, forming a complex network of protein-protein interactions called the interactome, Dr. Cheng explains. This becomes even more complicated when disease-causing DNA mutations are introduced into the mix. Some genes can be mutated in many ways to cause the same disease, meaning one condition can be associated with many interactomes arising from just one differently mutated protein.

    Drug developers are left with tens of thousands of potential disease-causing interactions to pick from — and that’s only after they generate the list based on the affected protein’s physical structures.

    Dr. Cheng sought to make an artificial intelligence (AI) tool to help genetic/genomic researchers and drug developers identify the most promising protein-protein interactions more easily, teaming up with Haiyuan Yu, PhD, director of the Cornell University Center for Innovative Proteomics. The group integrated massive amounts of data from multiple sources including:

    • Genomic sequences from almost 100,000 individuals who were either born with disease-causing mutations or acquired them later in life (usually cancer).
    • Physical three-dimensional structures of over 16,000 human proteins, and data on how DNA mutations impact those structures.
    • Known interactions between almost 300,000 different protein-protein pairs.

    Their resulting database allows researchers to navigate the interactome for more than 10,500 diseases, from alopecia to von Willebrand Disease.

    Researchers who identified a disease-associated mutation can input it into PIONEER to receive a ranked list of protein-protein interactions that contribute to the disease and can potentially be treated with a drug. Scientists can search for a disease by name to receive a list of potential disease-causing protein interactions that they can then go on to research. PIONEER is designed to help biomedical researchers who specialize in almost any disease across categories including autoimmune, cancer, cardiovascular, metabolic, neurological and pulmonary.

    The team validated their database’s predictions in the lab, where they made almost 3,000 mutations on over 1,000 proteins and tested their impact on almost 7,000 protein-protein interaction pairs. Preliminary research based on these findings is already underway to develop and test treatments for lung and endometrial cancers. The team also demonstrated that their model’s protein-protein interaction mutations can predict:

    • Survival rates and prognoses for various cancer types, including sarcoma, a rare but potentially deadly cancer.
    • Anti-cancer drug responses in large pharmacogenomics databases.

    The researchers also experimentally validated that protein-protein interaction mutations between the proteins NRF2 and KEAP1 can predict tumor growth in lung cancer, offering a novel target for targeted cancer therapeutic development.

    “The resources needed to conduct interactome studies poses a significant barrier to entry for most genetic researchers,” says Dr. Cheng. “We hope PIONEER can overcome these barriers computationally to lessen the burden and grant more scientists with the ability to advance new therapies.”